Concepedia

S.M. Tolaney

ST

Statistics

Publications

1

Citations

18

H-Index

1

Active since

2022

Affiliations

Gilead Sciences (United States)(Current)

S.M. Tolaney is an author at Gilead Sciences (United States) specializing in programmed death-ligand 1 targeting, pharmacology, and triple-negative breast cancer therapy.

Publications per year

2022–2022

1

Publications

1

276TiP ASCENT-04/KEYNOTE-D19: Phase III study of sacituzumab govitecan (SG) plus pembrolizumab (pembro) vs treatment of physician’s choice (TPC) plus pembro in first-line (1L) programmed death-ligand 1-positive (PD-L1+) metastatic triple-negative breast cancer (mTNBC)

S.M. Tolaney, E. de Azambuja, L.A. Emens et al. · Annals of Oncology · 2022 · 18 citations · Full text

, , +16

1–1 of 1